StemCells Seeks $20M in Stock Placement with Investors | GenomeWeb

NEW YORK (GenomeWeb) – StemCells today said that it intends to place common stock and warrants with two institutional investors with the aim of raising $20 million in gross proceeds.

The Newark, Calif.-based developer of stem cell therapies and research tools said that the offer includes the sale of around 11.3 million shares of common stock and short-term warrants for the purchase of up to an additional 9.6 million shares of common stock. It didn't name the two institutional investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.